Interleukin-18 and the Pathogenesis of Inflammatory Diseases

Seminars in Nephrology

Volumn 27, Issue 1, 2007, Pages 98-114

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cytokines; inflammation; interferon gamma

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; INTERLEUKIN 1F7; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; RECEPTOR ANTIBODY; SOLUBLE INTERLEUKIN 18 RECEPTOR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; ISCHEMIA; MACROPHAGE ACTIVATION; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODIES; CASPASE 1; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; RECEPTORS, INTERLEUKIN-18; RECEPTORS, PURINERGIC P2; TH1 CELLS; TH2 CELLS;

EID: 33847336449     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.09.013     Document Type: Article

References (113)

1. Amerio P., Frezzolini A., Abeni D., et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th1, Th2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 20 (2002) 535-538
2. lpr mice with autoimmune lupus nephritis. Arthritis Rheum 46 (2002) 3083-3095
3. Esfandiari E., McInnes I.B., Lindop G., et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol 167 (2001) 5338-5347
4. Bossu P., Neumann D., Del Giudice E., et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci U S A 100 (2003) 14181-14186
5. Okamura H., Tsutsui H., Komatsu T., et al. Cloning of a new cytokine that induces interferon-g. Nature 378 (1995) 88-91
6. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005) 479-490
7. Ghayur T., Banerjee S., Hugunin M., et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386 (1997) 619-623
8. Gu Y., Kuida K., Tsutsui H., et al. Activation of interferon-g inducing factor mediated by interleukin-1b converting enzyme. Science 275 (1997) 206-209
9. Mariathasan S., Newton K., Monack D.M., et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430 (2004) 213-218
10. Fantuzzi G., Puren A.J., Harding M.W., Livingston D.J., and Dinarello C.A. IL-18 regulation of IFN-g production and cell proliferation as revealed in interleukin-1b converting enzyme-deficient mice. Blood 91 (1998) 2118-2125
11. Nakanishi K., Yoshimoto T., Tsutsui H., and Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12 (2001) 53-72
12. Siegmund B., Lehr H.A., Fantuzzi G., and Dinarello C.A. IL-1beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 98 (2001) 13249-13254
13. Siegmund B., Fantuzzi G., Rieder F., et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-g and TNF-a production. Am J Physiol 281 (2001) R1264-R1273
14. Gatti S., Beck J., Fantuzzi G., Bartfai T., and Dinarello C.A. Effect of interleukin-18 on mouse core body temperature. Am J Physiol 282 (2002) R702-R709
15. Li S., Goorha S., Ballou L.R., and Blatteis C.M. Intracerebroventricular interleukin-6, macrophage inflammatory protein-1 beta and IL-18: pyrogenic and PGE(2)-mediated?. Brain Res 992 (2003) 76-84
16. Reznikov L.L., Kim S.H., Westcott J.Y., et al. IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci U S A 97 (2000) 2174-2179
17. Lee J.K., Kim S.H., Lewis E.C., Azam T., Reznikov L.L., and Dinarello C.A. Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci U S A 101 (2004) 8815-8820
18. Kim S.H., Han S.Y., Azam T., Yoon D.Y., and Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22 (2005) 131-142
19. Joosten L.A., van De Loo F.A., Lubberts E., et al. An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol 165 (2000) 6553-6558
20. Carrascal M.T., Mendoza L., Valcarcel M., et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 63 (2003) 491-497
21. Randle J.C., Harding M.W., Ku G., Schonharting M., and Kurrle R. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs 10 (2001) 1207-1209
22. Novick D., Kim S.-H., Fantuzzi G., Reznikov L., Dinarello C.A., and Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10 (1999) 127-136
23. Novick D., Schwartsburd B., Pinkus R., et al. A novel IL-18BP ELISA shows elevated serum il-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14 (2001) 334-342
24. Kim S.-H., Eisenstein M., Reznikov L., et al. Structural requirements of six naturally occurring isoforms of the interleukin-18 binding protein to inhibit interleukin-18. Proc Natl Acad Sci U S A 97 (2000) 1190-1195
25. Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., and Tschopp J. NALP3 forms an IL-1b processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity 20 (2004) 319-325
26. Aganna E., Martinon F., Hawkins P.N., et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46 (2002) 2445-2452
27. Hawkins P.N., Lachmann H.J., Aganna E., and McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50 (2004) 607-612
28. Coeshott C., Ohnemus C., Pilyavskaya A., et al. Converting enzyme-independent release of TNFa and IL-1b from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3. Proc Natl Acad Sci U S A 96 (1999) 6261-6266
29. Sugawara S., Uehara A., Nochi T., et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 167 (2001) 6568-6575
30. Faggioni R., Cattley R.C., Guo J., et al. IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 167 (2001) 5913-5920
31. Pomerantz B.J., Reznikov L.L., Harken A.H., and Dinarello C.A. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 98 (2001) 2871-2876
32. Melnikov V.Y., Ecder T., Fantuzzi G., et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 107 (2001) 1145-1152
33. Perregaux D.G., McNiff P., Laliberte R., Conklyn M., and Gabel C.A. ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J Immunol 165 (2000) 4615-4623
34. Solle M., Labasi J., Perregaux D.G., et al. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 276 (2001) 125-132
35. Laliberte R.E., Eggler J., and Gabel C.A. ATP treatment of human monocytes promotes caspase-1 maturation and externalization. J Biol Chem 274 (1999) 36944-36951
36. Baraldi P.G., del Carmen Nunez M., Morelli A., Falzoni S., Di Virgilio F., and Romagnoli R. Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. J Med Chem 46 (2003) 1318-1329
37. Gardella S., Andrei C., Costigliolo S., Poggi A., Zocchi M.R., and Rubartelli A. Interleukin-18 synthesis and secretion by dendritic cells are modulated by interaction with antigen-specific T cells. J Leukoc Biol 66 (1999) 237-241
38. Gardella S., Andrei C., Poggi A., Zocchi M.R., and Rubartelli A. Control of interleukin-18 secretion by dendritic cells: role of calcium influxes. FEBS Lett 481 (2000) 245-248
39. Kato Z., Jee J., Shikano H., et al. The structure and binding mode of interleukin-18. Nat Struct Biol 10 (2003) 966-971
40. Azam T., Novick D., Bufler P., et al. Identification of a critical Ig-like domain in IL-18 receptor alpha and characterization of a functional IL-18 receptor complex. J Immunol 171 (2003) 6574-6580
41. Casadio R., Frigimelica E., Bossu P., et al. Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex. FEBS Lett 499 (2001) 65-68
42. Reznikov L.L., Kim S.H., Zhou L., et al. The combination of soluble IL-18Ra and IL-18Rb chains inhibits IL-18-Induced IFN-g. J Interferon Cytokine Res 22 (2002) 593-601
43. Kumar S., McDonnell P.C., Lehr R., et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 275 (2000) 10308-10314
44. Pan G., Risser P., Mao W., et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL- 1Rrp. Cytokine 13 (2001) 1-7
45. Kumar S., Hanning C.R., Brigham-Burke M.R., et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 18 (2002) 61-71
46. Bufler P., Azam T., Gamboni-Robertson F., et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A 99 (2002) 13723-13728
47. Novick D., Engelmann H., Wallach D., Leitner O., Revel M., and Rubinstein M. Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr 510 (1990) 331-337
48. Engelmann H., Novick D., and Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265 (1990) 1531-1536
49. Kim S.H., Azam T., Novick D., et al. Identification of amino acid residues critical for biological activity in human interleukin-18. J Biol Chem 14 (2002) 14
50. Dinarello C.A. The many worlds of reducing interleukin-1. Arthritis Rheum 52 (2005) 1960-1967
51. Hurgin V., Novick D., and Rubinstein M. The promoter of IL-18 binding protein: activation by an IFN-gamma-induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc Natl Acad Sci U S A 99 (2002) 16957-16962
52. Paulukat J., Bosmann M., Nold M., et al. Expression and release of IL-18 binding protein in response to IFNg. J Immunol 167 (2001) 7038-7043
53. Fantuzzi G., Reed D., Qi M., Scully S., Dinarello C.A., and Senaldi G. Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity. Eur J Immunol 31 (2001) 369-375
54. Siegmund B., Sennello J.A., Lehr H.A., Senaldi G., Dinarello C.A., and Fantuzzi G. Interferon regulatory factor-1 as a protective gene in intestinal inflammation: role of TCR gamma delta T cells and interleukin-18-binding protein. Eur J Immunol 34 (2004) 2356-2364
55. Xiang Y., and Moss B. Correspondence of the functional epitopes of poxvirus and human interleukin-18-binding proteins. J Virol 75 (2001) 9947-9954
56. Xiang Y., and Moss B. Determination of the functional epitopes of human interleukin-18- binding protein by site-directed mutagenesis. J Biol Chem 276 (2001) 17380-17386
57. Maeno N., Takei S., Imanaka H., et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 50 (2004) 1935-1938
58. Dinarello C.A. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 74 (2005) 40-47
59. Ottenhoff T.H., Verreck F.A., Lichtenauer-Kaligis E.G., Hoeve M.A., Sanal O., and van Dissel J.T. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 32 (2002) 97-105
60. Wei X.Q., Leung B.P., Arthur H.M., McInnes I.B., and Liew F.Y. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 166 (2001) 517-521
61. Plater-Zyberk C., Joosten L.A., Helsen M.M., et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108 (2001) 1825-1832
62. Kim S.H., Reznikov L.L., Stuyt R.J., et al. Functional reconstitution and regulation of IL-18 activity by the IL- 18R beta chain. J Immunol 166 (2001) 148-154
63. Neumann D., and Martin M.U. Interleukin-12 upregulates the IL-18Rb chain in BALB/c thymocytes. J Interferon Cytokine Res 21 (2001) 635-642
64. Lugo-Villarino G., Maldonado-Lopez R., Possemato R., Penaranda C., and Glimcher L.H. T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci U S A 100 (2003) 7749-7754
65. Cardoso S.M., DeFor T.E., Tilley L.A., Bidwell J.L., Weisdorf D.J., and MacMillan M.L. Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. Br J Haematol 126 (2004) 704-710
66. Min C.K., Maeda Y., Lowler K., et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T cell subsets after experimental allogeneic bone marrow transplantation. Blood 104 (2004) 3393-3399
67. Reddy P., and Ferrara J.L. Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med 141 (2003) 365-371
68. Hoshino T., Yagita H., Ortaldo J.R., Wiltrout R.H., and Young H.A. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol 30 (2000) 1998-2006
69. Kawase Y., Hoshino T., Yokota K., et al. Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with targeted interleukin-18 expression in the skin. J Invest Dermatol 121 (2003) 502-509
70. Konishi H., Tsutsui H., Murakami T., et al. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc Natl Acad Sci U S A 99 (2002) 11340-11345
71. Nakanishi K., Yoshimoto T., Tsutsui H., and Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19 (2001) 423-474
72. Kaser A., Kaser S., Kaneider N.C., Enrich B., Wiedermann C.J., and Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 103 (2004) 648-655
73. Raeburn C.D., Dinarello C.A., Zimmerman M.A., et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol 283 (2002) H650-H657
74. Friteau L., Francesconi E., Lando D., Dugas B., and Damais C. Opposite effect of interferon-g on PGE2 release from interleukin-1- stimulated human monocytes or fibroblasts. Biochem Biophys Res Commun 157 (1988) 1197-1204
75. Mallat Z., Heymes C., Corbaz A., et al. Evidence for altered interleukin (IL)-18 pathway in human heart failure. FASEB J 18 (2004) 1752-1754
76. Whitman S.C., Ravisankar P., and Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 90 (2002) E34-E38
77. Gerdes N., Sukhova G.K., Libby P., Reynolds R.S., Young J.L., and Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 195 (2002) 245-257
78. Mallat Z., Corbaz A., Scoazec A., et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 89 (2001) E41-E45
79. Parikh C.R., Jani A., Melnikov V.Y., Faubel S., and Edelstein C.L. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 43 (2004) 405-414
80. Parikh C.R., Abraham E., Ancukiewicz M., and Edelstein C.L. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the ICU. J Am Soc Nephrol (2005) In press
81. Parikh C.R., Mishra J., Thiessen-Philbrook H., et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 70 (2006) 199-203
82. Netea M.G., Joosten L.A., Lewis E., et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 12 (2006) 650-656
83. Stuyt R.J., Netea M.G., Verschueren I., Dinarello C.A., Kullberg B.J., and van der Meer J.W. Interleukin-18 does not modulate the acute-phase response. J Endotoxin Res 11 (2005) 85-88
84. Puren A.J., Fantuzzi G., and Dinarello C.A. Gene expression, synthesis and secretion of IL-1b and IL-18 are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci U S A 96 (1999) 2256-2261
85. Mazodier K., Marin V., Novick D., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106 (2005) 3483-3489
86. Mencacci A., Bacci A., Cenci E., et al. Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun 68 (2000) 5126-5131
87. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor-a-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
88. Mohan A.K., Cote T.R., Block J.A., Manadan A.M., Siegel J., and Braun M.M. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39 (2004) 295-299
89. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004) 1261-1265
90. Ehlers S., Benini J., Kutsch S., Endres R., Rietschel E.T., and Pfeffer K. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun 67 (1999) 3571-3579
91. Mohan V.P., Scanga C.A., Yu K., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 69 (2001) 1847-1855
92. Sugawara I., Yamada H., Kaneko H., Mizuno S., Takeda K., and Akira S. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene- disrupted mice. Infect Immun 67 (1999) 2585-2589
93. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52 (2005) 1766-1772
94. Sivakumar P.V., Westrich G.M., Kanaly S., et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50 (2002) 812-820
95. Ten Hove T., Corbaz A., Amitai H., et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 121 (2001) 1372-1379
96. Wirtz S., Becker C., Blumberg R., Galle P.R., and Neurath M.F. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 168 (2002) 411-420
97. Smeets R.L., van de Loo F.A., Arntz O.J., Bennink M.B., Joosten L.A., and van den Berg W.B. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 10 (2003) 1004-1011
98. Maecker H.T., Hansen G., Walter D.M., DeKruyff R.H., Levy S., and Umetsu D.T. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 166 (2001) 959-965
99. Im S.H., Barchan D., Maiti P.K., Raveh L., Souroujon M.C., and Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J 15 (2001) 2140-2148
100. Furlan R., Martino G., Galbiati F., et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 163 (1999) 2403-2409
101. Faggioni R., Jones-Carson J., Reed D.A., et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A 97 (2000) 2367-2372
102. Fantuzzi G., Banda N.K., Guthridge C., et al. Generation and characterization of mice transgenic for human IL-18-binding protein isoform a. J Leukoc Biol 74 (2003) 889-896
103. Tsutsui H., Kayagaki N., Kuida K., et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 11 (1999) 359-367
104. Fantuzzi G., Reed D.A., and Dinarello C.A. IL-12-induced IFNg is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 104 (1999) 761-767
105. Netea M.G., Fantuzzi G., Kullberg B.J., et al. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol 164 (2000) 2644-2649
106. Vidal-Vanaclocha F., Fantuzzi G., Mendoza L., et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A 97 (2000) 734-739
107. Takeuchi D., Yoshidome H., Kato A., et al. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology 39 (2004) 699-710
108. Hoshino K., Tsutsui H., Kawai T., et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 162 (1999) 5041-5044
109. Okamoto M., Kato S., Oizumi K., et al. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 99 (2002) 1289-1298
110. Itoi H., Fujimori Y., Tsutsui H., et al. Involvement of interleukin-18 in acute graft-versus-host disease in mice. Transplantation 78 (2004) 1245-1250
111. Kinoshita K., Yamagata T., Nozaki Y., et al. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J Immunol 173 (2004) 5312-5318
112. Cheung H., Chen N.J., Cao Z., Ono N., Ohashi P.S., and Yeh W.C. Accessory protein-like is essential for IL-18-mediated signaling. J Immunol 174 (2005) 5351-5357
113. Takagi H., Kanai T., Okazawa A., et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand J Gastroenterol 38 (2003) 837-844